This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Colloidal Particle-based Immunoassay (CPIA) Development
In recent years, the use of immunoassays has become widespread in veterinary medicine, particularly for the diagnosis of animal diseases. Among the various immunoassay formats, colloidal particle-based immunoassay (CPIA) has emerged as a promising technology due to its high sensitivity, specificity, and versatility. At BioVenic, we provide our clients with a veterinary CPIA development service that meets research requirement.
Advantages of CPIA
Higher sensitivity and specificity
The large surface area of colloidal particles increases the opportunity for analyte-particle interactions that can amplify the signal or reduce background noise.
Faster, simpler programs
Colloidal particles can be easily coupled with immunological reagents and detected by various methods.
Higher throughput, lower cost
Colloidal particles are relatively inexpensive and available in multiplexed or miniaturized form.
Higher adaptability and refactorability
Colloidal particles can be modified with different functional groups or biomolecules to target various analytes.
Fig. 1 Schematic illustration of CPIA.2
Veterinary CPIA Development Services
BioVenic is a leader in veterinary CPIA development, offering a range of services to support the development and optimization of CPIA assays for a wide range of veterinary analytes including hormones, cytokines, and infectious agents. Our development services involve multiple steps including antigen preparation, particle coating, antibody labeling, signal detection, and production of validated CPIA tests for our clients. The CPIA development services we provide guarantee the reliability of each development step and the accuracy of the results.
Options for Particles
|
|
|
|
|
Magnetic particles
Nanoparticles
Veterinary CPIA Development Process
The veterinary CPIA development process is critical to ensure the accuracy and specificity of the assay. Our development process steps are as follows:
The selection of colloidal particles is critical to the performance of the assay. Our team carefully selects the appropriate colloidal particles based on the specific needs of the assay.
Our development service enabled the conjugation of the detection reagent to the surface of the colloidal particle, which determines the sensitivity and specificity of the assay.
We help optimize the assay to ensure maximum sensitivity and specificity. This step includes determining the optimal concentration of the detection reagent, incubation time, and temperature.
To validate veterinary CPIA results, we employ positive and negative controls, build calibration curves with known analyte concentrations, perform validation with samples of known concentrations, assess precision, determine sensitivity and detection limits, assess potential cross-reactivity, etc.
Our Service Flow Chart
Why Choose Us?
Custom CPIA Development
We provide custom CPIA development services to meet the specific needs of customers, such as colloidal particles, species, and target selection.
Advanced Technology
Our advanced equipment and facilities ensure our clients receive quality veterinary CPIA development services.
Highly Trained Staff
Our scientists have a proven track record of success developing CPIA assays for a wide variety of analytes.
BioVenic takes immense pride in offering specialized veterinary CPIA development services to our valued clientele. We assist in developing veterinary colloidal particle-based diagnostic immunoassay for unique applications, such as the detection of veterinary pathogens and animal disease biomarkers. Should you require our technical expertise or guidance, please do not hesitate to contact us.
References
- O'Connor Jr, Thomas P., et al. "Immunoassay applications in veterinary diagnostics." The immunoassay handbook (2013): 623.
- Mu, Yi, et al. "Development and assessment of a novel gold immunochromatographic assay for the diagnosis of schistosomiasis japonica." Frontiers in Immunology 14 (2023): 1165480.